InSite Vision to Announce First Quarter 2008 Financial Results and Hold Conference Call on May 8, 2008

2008-04-24 23:55:20 -

www.insitevision.com - InSite Vision Incorporated (AMEX:ISV) announced today that it will release results for the first quarter 2008 on Thursday, May 8, 2008.

S. Kumar Chandrasekaran, Ph.D., Chairman and Chief Executive Officer, will also host a conference call beginning at 4:30 p.m. Eastern Daylight Time on Thursday, May 8, 2008 to discuss these results.

Analysts and investors can listen to the conference call by dialing (877) 407-0778 for domestic callers and (201) 689-8565 for international callers. A telephone replay will be available for 48 hours following the conclusion of the call by dialing (877) 660-6853 for domestic callers and (201) 612-7415 for international callers. All callers will need to enter the account number 286 and conference ID 283202.

The live conference call will also be webcast and available at www.InvestorCalendar.com as well as on the Investor Relations page of the Company's website at www.insitevision.com. A recording of the call will be available for 90 days following completion of the conference call. In addition, the Company's first quarter 2008 earnings release will be posted to the Company's web site and furnished to the Securities and Exchange Commission on a Form 8-K prior to the conference call described above.

About InSite Vision

InSite Vision develops novel topical anti-infective products, including AzaSite(R) (azithromycin ophthalmic solution) 1% which was launched in the United States by Inspire Pharmaceuticals for the topical treatment of bacterial conjunctivitis (pink eye). InSite has filed a New Drug Submission (NDS) with Health Canada seeking regulatory approval to market AzaSite in Canada. In addition, InSite signed licensing and distribution agreements with Shin Poong Pharm in South Korea; and with Bioceutica, Inc. for four countries in South America; and is seeking other international partners for commercialization and distribution of AzaSite.

InSite is pursuing the expansion of its portfolio of anti-infective ophthalmic products to include ISV-502 (AzaSite Plus(TM)) in Phase 3 pivotal trials as a product candidate directed at treating eye and eye lid infections, currently an unmet need particularly prevalent among the growing elderly population. In addition, InSite is evaluating the use of its product platform for ear infections with the product candidate, AzaSite Otic(TM) in preclinical development. Additional information is available about the company at: www.insitevision.com.

InSite Vision
Joyce Strand, 510-747-1220